Lilly, With Tirzepatide Supply Issues Addressed, Raises Guidance By $3bn

Obesity, Diabetes Blockbusters Lead 36% Revenue Growth

 
• By Joseph Haas
  
Lilly corporate center
Lilly posted 36% year-over-year growth during Q2 2024 • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business